Gallbladder Cancer – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Gallbladder Cancer – Pipeline Review, H2 2019’, provides an overview of the Gallbladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gallbladder Cancer

– The report reviews pipeline therapeutics for Gallbladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gallbladder Cancer therapeutics and enlists all their major and minor projects

– The report assesses Gallbladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gallbladder Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Advenchen Laboratories LLC

Almac Discovery Ltd

Alphamab Oncology

Andes Biotechnologies

Apexian Pharmaceuticals Inc

Apollomics Inc

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Bristol-Myers Squibb Co

Delta-Fly Pharma Inc

Diverse Biotech Inc

Eisai Co Ltd

Eli Lilly and Co

Faron Pharmaceuticals Oy

Hutchison MediPharma Ltd

Infinity Pharmaceuticals Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Karus Therapeutics Ltd

Kringle Pharma Inc

Leap Therapeutics Inc

Lokon Pharma AB

Merck & Co Inc

Mina Therapeutics Ltd

Molecular Templates Inc

Novartis AG

NuCana Plc

OncoTherapy Science Inc

Pfizer Inc

Rafael Pharmaceuticals Inc

Shanghai Haihe Biopharma Co Ltd

Shanghai Junshi Bioscience Co Ltd

Sinocelltech Ltd

SMT bio Co Ltd

Taiho Pharmaceutical Co Ltd

TOT Biopharm Co Ltd

Turning Point Therapeutics Inc

VasGene Therapeutics Inc

XuanZhu Pharma Co Ltd

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Gallbladder Cancer Overview 5

Gallbladder Cancer Therapeutics Development 6

Gallbladder Cancer Therapeutics Assessment 10

Gallbladder Cancer Companies Involved in Therapeutics Development 18

Gallbladder Cancer Drug Profiles 27

Gallbladder Cancer Dormant Projects 197

Gallbladder Cancer Discontinued Products 198

Appendix 199

List of Tables

List of Tables

Number of Products under Development for Gallbladder Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Gallbladder Cancer – Pipeline by 4SC AG, H2 2019

Gallbladder Cancer – Pipeline by Advenchen Laboratories LLC, H2 2019

Gallbladder Cancer – Pipeline by Almac Discovery Ltd, H2 2019

Gallbladder Cancer – Pipeline by Alphamab Oncology, H2 2019

Gallbladder Cancer – Pipeline by Andes Biotechnologies, H2 2019

Gallbladder Cancer – Pipeline by Apexian Pharmaceuticals Inc, H2 2019

Gallbladder Cancer – Pipeline by Apollomics Inc, H2 2019

Gallbladder Cancer – Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Gallbladder Cancer – Pipeline by AstraZeneca Plc, H2 2019

Gallbladder Cancer – Pipeline by Bayer AG, H2 2019

Gallbladder Cancer – Pipeline by BeiGene Ltd, H2 2019

Gallbladder Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2019

Gallbladder Cancer – Pipeline by Delta-Fly Pharma Inc, H2 2019

Gallbladder Cancer – Pipeline by Diverse Biotech Inc, H2 2019

Gallbladder Cancer – Pipeline by Eisai Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Eli Lilly and Co, H2 2019

Gallbladder Cancer – Pipeline by Faron Pharmaceuticals Oy, H2 2019

Gallbladder Cancer – Pipeline by Hutchison MediPharma Ltd, H2 2019

Gallbladder Cancer – Pipeline by Infinity Pharmaceuticals Inc, H2 2019

Gallbladder Cancer – Pipeline by Ipsen SA, H2 2019

Gallbladder Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Karus Therapeutics Ltd, H2 2019

Gallbladder Cancer – Pipeline by Kringle Pharma Inc, H2 2019

Gallbladder Cancer – Pipeline by Leap Therapeutics Inc, H2 2019

Gallbladder Cancer – Pipeline by Lokon Pharma AB, H2 2019

Gallbladder Cancer – Pipeline by Merck & Co Inc, H2 2019

Gallbladder Cancer – Pipeline by Mina Therapeutics Ltd, H2 2019

Gallbladder Cancer – Pipeline by Molecular Templates Inc, H2 2019

Gallbladder Cancer – Pipeline by Novartis AG, H2 2019

Gallbladder Cancer – Pipeline by NuCana Plc, H2 2019

Gallbladder Cancer – Pipeline by OncoTherapy Science Inc, H2 2019

Gallbladder Cancer – Pipeline by Pfizer Inc, H2 2019

Gallbladder Cancer – Pipeline by Rafael Pharmaceuticals Inc, H2 2019

Gallbladder Cancer – Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Sinocelltech Ltd, H2 2019

Gallbladder Cancer – Pipeline by SMT bio Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by TOT Biopharm Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Turning Point Therapeutics Inc, H2 2019

Gallbladder Cancer – Pipeline by VasGene Therapeutics Inc, H2 2019

Gallbladder Cancer – Pipeline by XuanZhu Pharma Co Ltd, H2 2019

Gallbladder Cancer – Pipeline by Zymeworks Inc, H2 2019

Gallbladder Cancer – Dormant Projects, H2 2019

Gallbladder Cancer – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Gallbladder Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports